20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
20/20 BioLabs (Nasdaq:AIDX) will attend the Sidoti Micro-Cap Virtual Conference on May 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
20/20 BioLabs (Nasdaq:AIDX) will attend the Sidoti Micro-Cap Virtual Conference on May 20, 2026. CEO Jonathan Cohen will host a presentation from 3:15 PM to 3:45 PM ET in Track 1 and participate in one-on-one investor meetings.
Topics include recently reported quarterly results, recent partnership and licensing activity, and plans to scale the OneTest platform. Investors can access the webcast and schedule meetings through the conference website or conference representatives.
Details
News Market Reaction – AIDX
On May 14, the day this news came out, AIDX closed 1.41% below the previous close.
Data tracked by StockTitan Argus for the May 14 session.
Key Figures
- Conference date
- May 20, 2026
- Sidoti Micro-Cap Virtual Conference presentation
Historical Context
-
Exclusive PSA velocity algorithm license to enhance OneTest cancer platform.
-
Evexia Diagnostics adds OneTest for Cancer to its practitioner platform.
-
FY2025 revenue growth, margin expansion, lower opex, private placement completion.
-
Maryland funding over $520,000 for firefighter cancer screenings via OneTest.
-
Exclusive U.S. license to integrate CKD prediction into Longevity platform.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that management will attend the upcoming Sidoti Micro-Cap Virtual Conference.
20/20 BioLabs’ Chief Executive Officer, Jonathan Cohen, will participate in one-on-one investor meetings and host a presentation from 3:15 PM ET to 3:45 PM ET in Track 1. Mr. Cohen will discuss the Company’s recently reported quarterly results, recent partnership and licensing activity, and the plans to scale the OneTest platform.
Sidoti Virtual Micro-Cap Virtual Conference
Date: Wednesday, May 20, 2026
Format: Presentation & Virtual 1x1 Meetings
Presentation: 3:15 – 3:45 PM ET in Track 1
Webcast: Click here
Attendee: Chief Executive Officer Jonathan Cohen
Conference Website: Click here
For more information on the Sidoti Micro-Cap Virtual Conference, or to schedule a one-on-one meeting with Jonathan Cohen, please contact your conference representative or you may also email your request to AIDX@mzgroup.us or call Chris Tyson at (949) 941-8235.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for Longevity, which measures inflammatory biomarkers, launched in February 2026. OneTest’s affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.
20/20 BioLabs’ pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab. The Company’s legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. For more information visit 2020biolabs.com.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.